No Cure, No Pay: The Future of Drug Marketing?
Executive Summary
For most other consumer goods, you'd expect to get your money back if the product didn't work. Not so for drugs, where many treatments don't work in at least a significant minority of patients--but payors and governments can't claim a refund. That may be about to change.
You may also be interested in...
The Cost-Sharing Solution: The New NICE Ticket
J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim? This article originally appeared in February 2009's RPM Report.
The Cost-Sharing Solution: The New NICE Ticket
J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim? This article originally appeared in February 2009's RPM Report.
The Cost-Sharing Solution: The New NICE Ticket
J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim?